H.C. Wainwright raised the firm’s price target on Corcept Therapeutics to $32 from $30 and keeps a Buy rating on the shares post the Q2 results. The analyst says the company’s growth momentum continues in Cushing’s syndrome.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics reports Q2 EPS 25c, consensus 15c
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- CORT Upcoming Earnings Report: What to Expect?
- Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Corcept announces publication of analysis of Phase 2 trial of relacorilant